Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center Identifier:
First received: February 21, 2008
Last updated: August 4, 2014
Last verified: August 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):